Clinical Trial

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Study acronym: BITE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Benralizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, benralizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-01-04; most recent amendment 2026-06-15.
Status change: Active, Not Recruiting → Completed 2026-04-14
Status change: Recruiting → Active, Not Recruiting 2021-03-04
Status change: Not Yet Recruiting → Recruiting 2017-05-08
Trial Details
NCT Number NCT03010436
Lead Sponsor National Jewish Health
Collaborators: AstraZeneca
Conditions Asthma
Enrollment 10 participants
Start Date 2017-04-15
Primary Completion 2019-07-25 (estimated)
Study Completion 2021-12 (estimated)
Updated on ClinicalTrials.gov 2021-03-08